Vanguard Group Inc Alvotech Call Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding ALVO
# of Institutions
24Shares Held
14.3MCall Options Held
100KPut Options Held
0-
Howard Marks Oaktree Capital Management LP | Los Angeles, Ca2.9MShares$35.3 Million0.68% of portfolio
-
Bracebridge Capital, LLC2.71MShares$32.9 Million35.14% of portfolio
-
Sculptor Capital LP New York, NY1.95MShares$23.7 Million0.76% of portfolio
-
Littlejohn & CO LLC1.22MShares$14.8 Million7.72% of portfolio
-
Morgan Stanley New York, NY826KShares$10 Million0.0% of portfolio
About Alvotech
- Ticker ALVO
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 248,650,000
- Market Cap $3.02B
- Description
- Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...